Ajanta Pharma Share Price Target 2026 — Analyst Forecast, Catalysts and Key Risks

Thu Apr 23 2026

The Ajanta Pharma share price target 2026 stands at Rs 3,108-3,607 as per analyst consensus — implying 17-36% upside from the current CMP of Rs 2,657. Investors tracking the Ajanta Pharma share price target 2026 need to understand the complete picture — the specific growth catalysts, FY27 earnings timeline, risks, and the bull vs bear case that will determine whether Ajanta Pharma (AJANTPHARM) achieves or misses this 12-month target. This article covers every dimension of the Ajanta Pharma share price target 2026 thesis — catalysts, risks, scenarios, analyst ratings, and key levels — updated April 2026.

Click Here — Get Free SEBI-registered Research on Ajanta Pharma on Univest.

Table of Contents

Ajanta Pharma Share Price Overview — April 2026

Company	Ajanta Pharma
NSE Symbol	AJANTPHARM
Sector	Pharma / Branded Generics / Africa Asia Export
CMP April 2026	Rs 2,657
52-Week High	Rs 3,212
52-Week Low	Rs 2,107
Market Cap	Rs 23,600 Cr
Trailing P/E	28x
Dividend FY26	Rs 30
Promoter Holding	66.2%
FII Holding	14.8%
12M Analyst Target	Rs 3,108-3,607
Upside from CMP	17-36%

Data from NSE/BSE and publicly available research. April 2026. Verify before investing.

Track live Ajanta Pharma price, FII/DII flows and analyst targets on the Univest Screener.

What Is Ajanta Pharma?

Get Free Analyst Research on Ajanta Pharma — Tap Here.

Ajanta Pharma (NSE: AJANTPHARM) exports branded generics to Africa and Asia in cardiac, ophthalmology, and dermatology — high-margin branded model vs commodity US generics. FY26 PAT grew 25% on Africa and domestic recovery.

Budget 2026-27 Impact on Pharma

Budget 2026-27’s pharma export promotion and PLI support Ajanta’s Africa and Asia market expansion.

Ajanta Pharma share price target 2026 — Short, 12-Month and Long-Term Horizons

Horizon	Target	Key Assumption
Short-Term 3-6 Months	Rs 3,108	Q4 FY26 results beat and technical recovery
12-Month Consensus	Rs 3,108-3,607	FY27 earnings delivery and macro normalisation
Long-Term FY27-28	20-30% above 12M	Full earnings recovery and sector re-rating
Bear Case	Rs 2,107 zone	FY27 miss and extended FII selling

Compare Ajanta Pharma with sector peers live on the Univest Screener.

5 Growth Catalysts Supporting the Ajanta Pharma share price target 2026

1. India Pharma Sector — Structural Growth Tailwind

India’s Pharma sector is expanding at 12-18% annually — driven by rising incomes, urbanisation, government policy, and the India structural growth story. Ajanta Pharma’s market position within this sector creates compounding runway that underpins the Ajanta Pharma share price target 2026 consensus of Rs 3,108-3,607. FY27 is the year analysts expect operating leverage to translate revenue growth into 18-22% PAT expansion, directly validating the analyst target.

2. FY27 Earnings Recovery — Primary Re-Rating Catalyst

After FY26 headwinds from US tariff uncertainty, FII outflows, and sector-specific pressures, analyst consensus projects Ajanta Pharma to deliver 15-20% PAT growth in FY27. Q4 FY26 results (April-May 2026) with positive FY27 guidance are the immediate trigger for re-rating toward the Ajanta Pharma share price target 2026 consensus of Rs 3,108-3,607. Track Q4 results live on the Univest Screener.

3. Competitive Moat — Defensible Market Position Built Over Decades

Ajanta Pharma holds a structural competitive moat in its Pharma segment — brand equity, distribution depth, technical capability, or customer relationships that take 10-15 years to replicate. This moat protects market share during competitive cycles and enables pricing power in upcycles — the structural argument for the premium valuation embedded in the Ajanta Pharma share price target 2026 of Rs 3,108-3,607.

4. RBI Rate Cut Cycle — Reducing Cost of Capital

India’s RBI rate cut cycle commenced in 2026 reduces Ajanta Pharma’s borrowing costs and stimulates end-customer demand for Pharma products. Lower interest rates improve EBITDA-to-PAT conversion — directly expanding EPS and supporting the Ajanta Pharma share price target 2026 of Rs 3,108-3,607 by making the earnings multiple more justifiable.

5. Budget 2026-27 Policy Alignment and Government Capex Support

Union Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption incentives create a positive policy backdrop for Ajanta Pharma’s Pharma business. Regulatory clarity and government spending certainty reduce operating risk — improving earnings visibility that directly supports the Ajanta Pharma share price target 2026 bull case.

Download the Univest iOS App or Android App for live Ajanta Pharma alerts and SEBI-registered research.

5 Risks That Could Impact the Ajanta Pharma share price target 2026

1. US Tariff and Global Macro Headwinds

The 26% US reciprocal tariff (April 2026) created FII outflow pressure across Indian equities including Ajanta Pharma. Prolonged US-India trade tension would reduce FY27 estimates by 5-10% — the key downside risk to the Ajanta Pharma share price target 2026 consensus of Rs 3,108-3,607.

2. Valuation at 28x Requires Consistent Execution

At 28x trailing P/E, Ajanta Pharma is priced for sustained growth. Any Q4 FY26 miss or FY27 guidance cut triggers multiple compression — the most immediate risk to the Ajanta Pharma share price target 2026. The Rs 2,107 52-week low zone is the key support and stop-loss reference.

3. Competition Intensifying in Pharma

Domestic and global competitors are investing aggressively in Ajanta Pharma’s Pharma market. Pricing pressure or market share erosion compresses revenue growth visibility and reduces the multiple supporting the Ajanta Pharma share price target 2026.

4. Input Cost and Supply Chain Volatility

Commodity prices, energy, and supply chain disruptions create quarterly earnings volatility. Any cost increase that cannot be passed through compresses EBITDA below analyst estimates — creating downside risk to the Ajanta Pharma share price target 2026 of Rs 3,108-3,607.

5. FII Selling Risk — 14.8% Institutional Holding

With 14.8% FII ownership, Ajanta Pharma is exposed to global risk-off events triggering institutional selling disconnected from fundamentals. FII exits temporarily suppress the stock below levels justified by the Ajanta Pharma share price target 2026 analyst consensus of Rs 3,108-3,607.

Ajanta Pharma Bull Case vs Bear Case — Ajanta Pharma share price target 2026

Scenario	Price Target	Probability	Trigger
Bull Case	3,607	Medium	FY27 earnings beat, FII re-entry, sector re-rating
Base Case	Rs 3,108-3,607	High	FY27 in-line earnings, stable macro
Bear Case	Rs 2,107 zone	Low	FY27 guidance cut, prolonged FII selling

Ajanta Pharma Share Price Reference Table

NSE Symbol	AJANTPHARM
CMP	Rs 2,657
52-Week High	Rs 3,212
52-Week Low	Rs 2,107
Market Cap	Rs 23,600 Cr
P/E	28x
Promoter	66.2%
FII	14.8%
Dividend FY26	Rs 30
Short-Term Target	Rs 3,108
12M Target	Rs 3,108-3,607
Upside	17-36%

Sources: NSE/BSE, Screener.in, publicly available analyst research. April 2026.

Analyst Ratings and Ajanta Pharma share price target 2026

Brokerage	Rating	Target	Key View
MOFSL	Buy	Rs 3,188	FY27 earnings recovery and Pharma sector leadership
YES Securities	Buy	Rs 3,241	Quality execution — accumulate at support levels
Kotak Institutional	Add	Rs 3,055	Monitor Q4 FY26 guidance — maintain position
JM Financial	Neutral	Consensus	Await Q4 FY26 result clarity before adding

Subscribe to Univest Pro for SEBI-registered entry, target and stop-loss on Ajanta Pharma.

How to Invest in Ajanta Pharma — 5 Steps

Step 1: Research on the Univest Screener

Search AJANTPHARM on univest.in/screeners. Review quarterly results, FII/DII trend, promoter holding, and analyst consensus on the Ajanta Pharma share price target 2026.

Step 2: Identify Entry Level

Ajanta Pharma at Rs 2,657 has key support near Rs 2,107. Plan entry near support with stop-loss 8-10% below entry. First resistance toward the Ajanta Pharma share price target 2026 recovery is Rs 3,108.

Step 3: Monitor Q4 FY26 Results

Q4 FY26 results (April-May 2026) are the near-term trigger. A beat with positive FY27 guidance triggers re-rating toward 3,607 — the bull case for the Ajanta Pharma share price target 2026.

Step 4: Position Sizing

Allocate maximum 3-5% of your portfolio to any single stock. Never invest more than you can hold for 2+ years through volatility.

Step 5: Track on the Univest App

Download the Univest iOS App or Android App for live price alerts and SEBI-registered research aligned with the Ajanta Pharma share price target 2026.

Conclusion — Ajanta Pharma share price target 2026

Ajanta Pharma (AJANTPHARM) at Rs 2,657 offers 17-36% potential upside to the 12-month Ajanta Pharma share price target 2026 consensus of Rs 3,108-3,607. The bull case to 3,607 requires FY27 earnings delivery and macro normalisation. The bear case (Rs 2,107 zone) materialises only on significant earnings disappointment. For long-term investors with a 2-3 year horizon, Ajanta Pharma at current levels presents a monitored entry opportunity. For more Ajanta Pharma share price target 2026 analysis and peer comparisons, visit Univest Blogs.

Disclaimer: Investment in the share market is subject to market risks. This article is for educational and informational purposes only and does not constitute investment advice. All analyst targets are estimates based on publicly available research as of April 2026 and are subject to change. Verify all data on NSE/BSE before investing. Consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions — Ajanta Pharma share price target 2026

Q: What is Ajanta Pharma share price target for 2026?

The 12-month Ajanta Pharma share price target 2026 analyst consensus is Rs 3,108-3,607 — implying 17-36% upside from CMP Rs 2,657. Bull case: 3,607. Bear case: Rs 2,107 zone. Track the live Ajanta Pharma share price target 2026 on the Univest Screener. These are analyst estimates, not guaranteed returns.

Q: Is Ajanta Pharma a good buy at Rs 2,657?

This article does not constitute investment advice. At Rs 2,657, Ajanta Pharma offers 17-36% upside to the Ajanta Pharma share price target 2026 consensus of Rs 3,108-3,607. Suitability depends on your risk tolerance and investment horizon. Consult a SEBI-registered financial advisor before investing.

Q: What is Ajanta Pharma 52-week high and low?

Ajanta Pharma’s 52-week high is Rs 3,212 and 52-week low is Rs 2,107. At the current CMP of Rs 2,657, the stock has corrected from its 52-week high — creating recovery potential for investors aligned with the Ajanta Pharma share price target 2026 thesis.

Q: What sector is Ajanta Pharma (AJANTPHARM) in?

Ajanta Pharma operates in the Pharma / Branded Generics / Africa Asia Export sector. India’s Pharma sector is growing structurally — driven by rising incomes, government policy, and India’s consumption expansion — underpinning the Ajanta Pharma share price target 2026 bull case.

Q: What are the main risks for the Ajanta Pharma share price target 2026 thesis?

Key risks: US tariff macro headwinds, valuation at 28x requiring consistent execution, competition in Pharma, input cost volatility, and FII selling pressure (14.8% holding). Monitor quarterly earnings closely.

Q: What is Ajanta Pharma’s market cap?

Ajanta Pharma has a market cap of Rs 23,600 Cr as of April 2026. At the Ajanta Pharma share price target 2026 of Rs 3,108-3,607, the implied market cap would reflect 17-36% appreciation on the current base.

Q: What is Ajanta Pharma dividend for FY26?

Ajanta Pharma’s FY26 dividend is Rs 30. Track dividend announcements on NSE or the Univest Screener. Dividend yield adds to the total return alongside the Ajanta Pharma share price target 2026 capital appreciation potential.

Q: How to buy Ajanta Pharma shares?

Buy Ajanta Pharma (AJANTPHARM) through any SEBI-registered broker on NSE. Research first on the Univest Screener, set a price alert at the Rs 2,107 support zone, and download the Univest App for SEBI-registered research on the Ajanta Pharma share price target 2026.